*School of Medical Sciences, State University of Campinas; †Center for Comprehensive Assistance to Women's Health (CAISM) - Dr José Aristodemo Pinotti Women's Hospital, State University of Campinas, Campinas; and ‡Jundiaí Medical School, Jundiaí, Brazil.
Int J Gynecol Cancer. 2014 Feb;24(2):321-8. doi: 10.1097/IGC.0000000000000057.
The objective of this study was to evaluate the impact of cervical cytology screening on the prevalence of cervical cytological results in women, as a function of age and test interval.
This is a cross-sectional study of cytology screening data of 2,002,472 tests obtained from previously screened women and 217,826 tests from unscreened women. The central cytopathology laboratory database was analyzed. The tests were collected for screening purposes from Campinas metropolitan region, Brazil. A prevalence ratio (PR) with a 95% confidence interval was calculated for the screened women, in relation to the unscreened women, and for different tests intervals. Protection afforded by screening (1-PR) was calculated.
For high-grade squamous intraepithelial lesion, the PR was 0.97 (0.83-1.13) for women aged 20 years or younger and 0.99 (0.86-1.14) for women aged 20 to 24 years, decreasing significantly in women aged 25 to 29 years (PR, 0.63 [0.52-0.76]). The PR for squamous cell carcinoma, adenocarcinoma in situ (AIS), and invasive adenocarcinoma showed a significant reduction in all age groups older than 30 years. For the age group ranging from 30 to 59 years, protection for squamous cell carcinoma, AIS, and invasive adenocarcinoma was 83% or higher for screening intervals from 1 to 5 years. Protective effect was not demonstrated for screening intervals longer than 5 years for AIS and invasive adenocarcinoma.
Cytology screening is effective at preventing cytological high-grade squamous intraepithelial lesion, squamous cell carcinoma, AIS, and invasive adenocarcinoma. On the basis of cytological results, protection against AIS and invasive adenocarcinoma was observed with screening intervals shorter than 5 years. Cytological screening in women 25 years or younger should be critically evaluated.
本研究旨在评估宫颈细胞学筛查对女性宫颈细胞学结果流行率的影响,以及年龄和检测间隔的作用。
这是一项对 2002472 例经筛查女性和 217826 例未经筛查女性的细胞学筛查数据进行的横断面研究。对中央细胞病理学实验室数据库进行了分析。这些检测是为了在巴西坎皮纳斯大都市区进行筛查而收集的。对筛查女性与未筛查女性的不同检测间隔进行了比值比(PR)及其 95%置信区间的计算。计算了筛查的保护率(1-PR)。
对于高级别鳞状上皮内病变,20 岁及以下女性的 PR 为 0.97(0.83-1.13),20-24 岁女性的 PR 为 0.99(0.86-1.14),而 25-29 岁女性的 PR 显著下降(PR,0.63 [0.52-0.76])。所有 30 岁以上年龄组的鳞状细胞癌、原位腺癌(AIS)和浸润性腺癌的 PR 均显著降低。对于 30-59 岁年龄组,1-5 年筛查间隔的鳞状细胞癌、AIS 和浸润性腺癌的保护率为 83%或更高。对于 AIS 和浸润性腺癌,超过 5 年的筛查间隔并未显示出保护作用。
细胞学筛查可有效预防细胞学高级别鳞状上皮内病变、鳞状细胞癌、AIS 和浸润性腺癌。基于细胞学结果,5 年以内的筛查间隔可预防 AIS 和浸润性腺癌。对于 25 岁及以下的女性,应慎重评估细胞学筛查。